<DOC>
	<DOCNO>NCT00098566</DOCNO>
	<brief_summary>RATIONALE : Studying long-term effect cancer treatment cancer survivor may help improve ability plan effective treatment follow-up care . PURPOSE : This phase II trial study long-term effect iodine I 131 tositumomab autologous bone marrow stem cell transplantation patient relapse refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Long-Term Effects Iodine I Tositumomab Autologous Bone Marrow Stem Cell Transplantation Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine progression-free survival overall survival patient relapse refractory B-cell non-Hodgkin 's lymphoma previously treat iodine I^131 tositumomab follow autologous bone marrow stem cell transplantation FHCRC protocols 296 , 521 , 792 , 915 . - Determine long-term toxic effect regimen patient . - Determine quality life patient treat regimen . OUTLINE : This long-term , follow-up study . Patients undergo test human anti-mouse antibody 1 , 3 12 month . Patients undergo physical examination , blood test , immune system assessment every 3 month 1 year annually thereafter . Thyroid , pulmonary , cardiac function assess 1 year annually need . Patients also undergo CT scan bone marrow biopsy ( clinically indicate ) annually 10 year . Quality life assess annually . PROJECTED ACCRUAL : A total 47 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell nonHodgkin 's lymphoma Relapsed refractory disease Previously treat myeloablative dos iodine I^131 tositumomab autologous bone marrow stem cell transplantation 1 follow phase I II protocol : FHCRC296 FHCRC521 FHCRC792 FHCRC915 PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>quality life</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
</DOC>